Neuland Labs Q4FY26 Total Income ₹788.7 Cr, EBITDA ₹319.4 Cr
Neuland Laboratories reported Q4FY26 results with total income at ₹788.7 crore (up 134.9% YoY) and EBITDA at ₹319.4 crore (up 448.6% YoY). PAT increased to ₹212.5 crore. CEO Saharsh Davuluri expressed satisfaction with the strong performance and future growth prospects driven by investments in peptide manufacturing and R&D.
The substantial increase in key financial metrics like revenue and profit, along with positive management outlook, is expected to have a significant positive impact on investor sentiment and the company's stock.
The company reported significant year-on-year growth in total income, EBITDA, and profit after tax, indicating strong financial performance. Management commentary is optimistic about future growth.
Neuland Laboratories Limited announced its financial results for the quarter and year ended March 31, 2026. The company reported a total income of ₹788.7 crore for Q4FY26, a significant increase of 134.9% compared to ₹335.8 crore in Q4FY25. EBITDA for the quarter stood at ₹319.4 crore, marking a substantial rise of 448.6% from ₹58.2 crore in the same period last year. The EBITDA margin improved to 40.5% from 17.3% in Q4FY25.
Profit Before Tax (PBT) for Q4FY26 was ₹287.0 crore, a 636.6% increase from ₹39.0 crore in Q4FY25. Consequently, Profit After Tax (PAT) surged to ₹212.5 crore, up 666.3% from ₹27.7 crore in the prior year quarter.
Commenting on the performance, Mr. Saharsh Davuluri, Chief Executive Officer and Managing Director, stated that the company ended FY26 on a strong note, in line with expectations, with good business visibility in the short to medium term. He highlighted the ongoing investments in Peptide Manufacturing and the new R&D Centre as key elements for future growth, with the business development strategy focused on attracting projects that support high-quality, sustainable growth.
The company will conduct an earnings call at 17:30 hrs IST on Tuesday, May 12, 2026, to discuss its performance. The press release originally shared had an error in the earning call link, which has now been corrected. The transcript of the conference call will be uploaded on the company website.
What to do with a filing like this
Neuland Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neuland Laboratories Limited. Read the original for the full detail.